FIGURE 4.

Response to tipifarnib in patients with Q61K HRAS-mutant, metastatic salivary cancer of the parotid gland. (A) Pretreatment, axial, contrast-enhanced, T1-weighted magnetic resonance imaging demonstrating a multilobulated and partially cystic mass (arrows) arising from the clivus prior to the initiation of tipifarnib and (B) a later marked reduction in the size and cystic nature of the mass after 8 months of tipifarnib therapy. (C) Axial contrast-enhanced computed tomography images in lung windows demonstrating a 50.2-mm, right middle lobe mass prior to the initiation of tipifarnib therapy and (D) a later reduction in the size of the mass to 27.8 mm after 5 months of tipifarnib therapy (patient 1).